PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2007 October; 8(4): 191.
Published online 2007 December 14. doi:  10.1208/pt0804104
PMCID: PMC2750690

Nanoemulsions as vehicles for transdermal delivery of aceclofenac

Abstract

The aim of the present study was to investigate the potential of a nanoemulsion formulation for transdermal delivery of aceclofenac. Various oil-in-water nanoemulsions were prepared by the spontaneous emulsification method. The nanoemulsion area was identified by constructing pseudoternary phase diagrams. The prepared nanoemulsions were subjected to different thermodynamic stability tests. The nanoemulsion formulations that passed thermodynamic stability tests were characterized for viscosity, droplet size, transmission electron microscopy, and refractive index. Transdermal permeation of aceclofenac through rat abdominal skin was determined by Franz diffusion cell. The in vitro skin permeation profile of optimized formulations was compared with that of aceclofenac conventional gel and nanoemulsion gel. A significant increase in permeability parameters such as steady-state flux (Jss), permeability coefficient (Kp), and enhancement ratio (Er) was observed in optimized nanoemulsion formulation F1, which consisted of 2% wt/wt of aceclofenac, 10% wt/wt of Labrafil®, 5% wt/wt of Triacetin®, 35.33% wt/wt of Tween 80®, 17.66% wt/wt of Transcutol P®, and 32% wt/wt of distilled water. The anti-inflammatory effects of formulation F1 showed a significant increase (P<.05) in percent inhibition value after 24 hours when compared with aceclofenac conventional gel and nanoemulsion gel on carrageenan-induced paw edema in rats. These results suggested that nanoemulsions are potential vehicles for improved transdermal delivery of aceclofenac.

Keywords: Aceclofenac, nanoemulsions, transdermal delivery, anti-inflammatory effects

Full Text

The Full Text of this article is available as a PDF (254K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Escribano E, Calpena AC, Queralt J, Obach R, Domenech J. Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula. Eur J Pharm Sci. 2003;19:203–210. doi: 10.1016/S0928-0987(03)00103-9. [PubMed] [Cross Ref]
2. Yamazaki R, Kawai S, Mastsuzaki T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol. 1997;329:181–187. [PubMed]
3. Gonzalez E, Cruz C, Nicolas R, Egido J, Herrero-Beaumont G. Long-term effects of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions. 1994;41:171–178. doi: 10.1007/BF02001912. [PubMed] [Cross Ref]
4. Yang JH, Kim Y, Kim KM. Preparation and evaluation of aceclofenac microemulsion for transdermal delivery system. Arch Pharm Res. 2002;25:534–540. doi: 10.1007/BF02976614. [PubMed] [Cross Ref]
5. Walters KA. Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft J, Guy RH, editors. Transdermal Drug Delivery, Developmental Issues and Research Initiatives. New York, NY: Marcel Dekker; 1989. pp. 197–246.
6. Shafiq S, Faiyaz S, Sushma T, Ahmad FJ, Khar RK, Ali M. Design and development of oral oil in water ramipril nanoemulsion formulation:in vitro andin vivo evaluation. J Biomed Nanotech. 2007;3:28–44. doi: 10.1166/jbn.2007.008. [Cross Ref]
7. Shafiq S, Faiyaz S, Sushma T, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227–243. doi: 10.1016/j.ejpb.2006.10.014. [PubMed] [Cross Ref]
8. Osborne DW, Ward AJ, Neil KJ. Microemulsions as topical delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug. J Pharm Pharmacol. 1991;43:450–454. [PubMed]
9. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv. 1996;71:135–140. doi: 10.1016/0031-6865(96)00003-9. [PubMed] [Cross Ref]
10. Delgado-Charro MB, Iglesias-Vilas G, Blanco-Mendez J, Lopez-Quintela MJ, Marty MA, Guy JP. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur J Pharm Biopharm. 1997;43:37–42. doi: 10.1016/S0939-6411(96)00016-1. [Cross Ref]
11. Dreher F, Walde P, Walter P, Wehrli E. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Rel. 1997;45:131–140. doi: 10.1016/S0168-3659(96)01559-3. [Cross Ref]
12. Schmalfus U, Neubart R, Wohlrab W. Modification of drug penetration into human skin using microemulsions. J Control Rel. 1997;46:279–285. doi: 10.1016/S0168-3659(96)01609-4. [Cross Ref]
13. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterization and transdermal drug delivery potentials of microemulsion systems. J Control Rel. 2000;69:421–433. doi: 10.1016/S0168-3659(00)00325-4. [PubMed] [Cross Ref]
14. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm. 2001;215:57–65. doi: 10.1016/S0378-5173(00)00674-8. [PubMed] [Cross Ref]
15. Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm. 2001;228:161–170. doi: 10.1016/S0378-5173(01)00827-4. [PubMed] [Cross Ref]
16. Lee PJ, Langer R, Shastri VP. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res. 2003;20:264–269. doi: 10.1023/A:1022283423116. [PubMed] [Cross Ref]
17. Kemken J, Ziegler A, Muller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res. 1992;9:554–558. doi: 10.1023/A:1015856800653. [PubMed] [Cross Ref]
18. Kreilgaard M. Dermal pharmacokinetics of microemulsion formulations determined byin-vitro microdialysis. Pharm Res. 2001;18:367–373. doi: 10.1023/A:1011067300397. [PubMed] [Cross Ref]
19. Kreilgaard M, Kemme MJB, Burggraaf J, Schoemaker RC, Cohen AF. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res. 2001;18:593–599. doi: 10.1023/A:1011068907416. [PubMed] [Cross Ref]
20. Ktistis G, Niopas I. A study on thein-vitro percutaneous absorption of propranolol from disperse systems. J Pharm Pharmacol. 1998;50:413–419. [PubMed]
21. Gasco MR, Gallarate M, Pattarino F. In vitro permeation of azelaic acid from viscosized microemulsions. Int J Pharm. 1991;69:193–196. doi: 10.1016/0378-5173(91)90361-Q. [Cross Ref]
22. Kriwet K, Muller-Goymann CC. Diclofenac release from phospholipid drug systems and permeation through excised human stratum corneum. Int J Pharm. 1995;125:231–242. doi: 10.1016/0378-5173(95)00130-B. [Cross Ref]
23. Trotta M. Influence of phase transformation on indomethacin release from microemulsions. J Control Rel. 1999;60:399–405. doi: 10.1016/S0168-3659(99)00094-2. [PubMed] [Cross Ref]
24. Baboota S, Shakeel F, Kohli K. Formulation and evaluation of once a day transdermal gels of diclofenac diethylamine. Methods Find Exp Clin Pharmacol. 2006;28:109–114. doi: 10.1358/mf.2006.28.2.977842. [PubMed] [Cross Ref]
25. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, et al. Formulation development and optimization using nanoemulsion technique: a technical note.AAPS PharmSciTech [serial online]. 2007;8:E28. [PMC free article] [PubMed]
26. Attwood D, Mallon C, Ktistis G, Taylor CJ. A study on factors influencing the droplet size in nonionic oil-in-water microemulsions. Int J Pharm. 1992;88:417–422. doi: 10.1016/0378-5173(92)90341-X. [Cross Ref]
27. Van-Abbe NJ, Nicholas P, Boon E. Exaggerated exposure in topical irritancy and sensitization testing. J Soc Cosmet Chem. 1975;26:173–187.
28. Winter CA. Anti-inflammatory testing methods: comparative evaluation of indomethacin and other agents. Nonsteroid Anti-inflammat Drugs. 1965;52:190–202.
29. Gosh MN. Fundamentals of Experimental Pharmacology. Kolkata, India: Hilton and Company; 2005. pp. 192–192.
30. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995;114:103–110. doi: 10.1016/0378-5173(94)00222-Q. [Cross Ref]
31. Eccleston J. Microemulsions. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. vol. 9. New York, NY: Marcel Dekker; 1995. pp. 375–421.
32. Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs, I: prescription design. J Control Rel. 2002;81:65–74. doi: 10.1016/S0168-3659(02)00049-4. [PubMed] [Cross Ref]
33. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121. doi: 10.1016/S0169-409X(00)00103-4. [PubMed] [Cross Ref]
34. Warisnoicharoen W, Lansley AB, Lawrence MJ. Light scattering investigations on dilute non-ionic oil-in-water microemulsions.AAPS PharmSciTech [serial online]. 2002;2:E12. [PMC free article] [PubMed]
35. Li P, Ghosh A, Wagner RF, Krill S, Joshi YM, Serajuddin ATM. Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. Int J Pharm. 2005;288:27–34. doi: 10.1016/j.ijpharm.2004.08.024. [PubMed] [Cross Ref]
36. Shinoda K, Kunieda H. Phase properties of emulsions: PIT and HLB. In: Schuster D, editor. Encyclopedia of Emulsion Technology. New York, NY: Marcel Dekker; 1983. pp. 337–367.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists